Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2717)
All Articles published online
|
Aug 14, 2006 (publication date) through Jun 5, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Mirbagheri SA, Hasibi M, Abouzari M, Rashidi A. Triple, standard quadruple and ampicillin-sulbactam-based quadruple therapies for H pylori eradication: A comparative three-armed randomized clinical trial. World J Gastroenterol 2006; 12(30): 4888-4891 [PMID: 16937475 DOI: 10.3748/wjg.v12.i30.4888] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v12/i30/4888.htm |
| Number | Citing Articles |
| 1 |
Nkengeh Tazinkeng, Joao Filipe Monteiro, Bill-Erich Mbianyor, Avis Anya Nowbuth, Monela Ntonifor, Claudia Evenge, Alick Nkhoma, Steven F Moss, Akwi W Asombang. Knowledge and approach towards Helicobacter pylori diagnosis and management among primary care physicians in Cameroon: a cross-sectional study. Transactions of The Royal Society of Tropical Medicine and Hygiene 2024; 118(5): 313 doi: 10.1093/trstmh/trad089
|
| 2 |
Gyu Young Pih, Kee Don Choi, Eun Jeong Gong, Hee Kyong Na, Ji Yong Ahn, Jeong Hoon Lee, Kee Wook Jung, Do Hoon Kim, Ho June Song, Gin Hyug Lee, Hwoon‐Yong Jung. Modified bismuth quadruple therapy with low‐dose metronidazole as first‐line therapy for Helicobacter pylori infection. Helicobacter 2021; 26(1) doi: 10.1111/hel.12759
|
| 3 |
Seyedali Seyedmajidi, Dariush Mirsattari, Homayoun Zojaji, Elahe Zanganeh, Mohammadreza Seyyedmajidi, Shohreh Almasi, Mohammadreza Zali. Penbactam for Helicobacter pylori eradication: A randomised comparison of quadruple and triple treatment schedules in an Iranian population. Arab Journal of Gastroenterology 2013; 14(1): 1 doi: 10.1016/j.ajg.2012.12.004
|
| 4 |
Hafez Fakheri, Zohreh Bari, Mohsen Aarabi, Reza Malekzadeh. <italic>Helicobacter pylori</italic> eradication in West Asia: A review. World Journal of Gastroenterology 2014; 20(30): 10355-10367 doi: 10.3748/wjg.v20.i30.10355
|
| 5 |
Anti-ulcer activity of NS-EA 51 – A fraction of Nigella sativa seed, in histamine plus pylorus-ligated and hypothermia plus restrain stressed rat models. Journal of Pharmacy Research 2013; 6(1): 16 doi: 10.1016/j.jopr.2012.11.007
|
| 6 |
Hafez Fakheri, Mehdi Saberi Firoozi, Zohreh Bari. Eradication of Helicobacter Pylori in Iran: A Review. Middle East Journal of Digestive Diseases 2017; 10(1): 5 doi: 10.15171/mejdd.2017.84
|
| 7 |
György M Buzás, Jolán Józan. Nitrofuran‐based regimens for the eradication of Helicobacter pylori infection. Journal of Gastroenterology and Hepatology 2007; 22(10): 1571 doi: 10.1111/j.1440-1746.2007.05082.x
|
| 8 |
Raquel Fernández-García, María Prada, Francisco Bolás-Fernández, M. Paloma Ballesteros, Dolores R. Serrano. Oral Fixed-Dose Combination Pharmaceutical Products: Industrial Manufacturing Versus Personalized 3D Printing. Pharmaceutical Research 2020; 37(7) doi: 10.1007/s11095-020-02847-3
|
| 9 |
Munmun Sarkar, Lakshmi Maganti, Nanda Ghoshal, Chitra Dutta. In silico quest for putative drug targets in Helicobacter pylori HPAG1: molecular modeling of candidate enzymes from lipopolysaccharide biosynthesis pathway. Journal of Molecular Modeling 2012; 18(5): 1855 doi: 10.1007/s00894-011-1204-3
|
| 10 |
Dariush Mirsattari, Homayoun Zojaji, Hamid Mahboubi, Mahsa Molaei, Faramarz Derakhshan, Mohammadreza Zali. Quadruple versus common triple-treatment regimens for Helicobacter pylori eradication in the Iranian population: A randomised study. Arab Journal of Gastroenterology 2010; 11(4): 187 doi: 10.1016/j.ajg.2010.09.001
|
| 11 |
Louis Anthony (Tony) Cox Jr, Douglas A. Popken. Assessing Potential Human Health Hazards and Benefits from Subtherapeutic Antibiotics in the United States: Tetracyclines as a Case Study. Risk Analysis 2010; 30(3): 432 doi: 10.1111/j.1539-6924.2009.01340.x
|
| 12 |
Lingyan He, Liang Zhang, Xiaofeng Liu, Xianghua Li, Mingyue Zheng, Honglin Li, Kunqian Yu, Kaixian Chen, Xu Shen, Hualiang Jiang, Hong Liu. Discovering Potent Inhibitors Against the β-Hydroxyacyl-Acyl Carrier Protein Dehydratase (FabZ) of Helicobacter pylori: Structure-Based Design, Synthesis, Bioassay, and Crystal Structure Determination. Journal of Medicinal Chemistry 2009; 52(8): 2465 doi: 10.1021/jm8015602
|
| 13 |
Chao-Sheng Cheng, Chih-Hao Chen, Yong-Chun Luo, Wen-Tin Chen, Shun-Ya Chang, Ping-Chiang Lyu, Mou-Chieh Kao, Hsien-Sheng Yin. Crystal structure and biophysical characterisation of Helicobacter pylori phosphopantetheine adenylyltransferase. Biochemical and Biophysical Research Communications 2011; 408(2): 356 doi: 10.1016/j.bbrc.2011.04.058
|
| 14 |
Maria Pina Dore, Hong Lu, David Y Graham. Role of bismuth in improvingHelicobacter pylorieradication with triple therapy. Gut 2016; 65(5): 870 doi: 10.1136/gutjnl-2015-311019
|
| 15 |
Samin Alihosseini, Reza Ghotaslou, Fatemah Sadeghpour Heravi, Zainab Ahmadian, Hamed Ebrahimzadeh Leylabadlo. Management of antibiotic-resistant Helicobacter pylori infection: current perspective in Iran. Journal of Chemotherapy 2020; 32(6): 273 doi: 10.1080/1120009X.2020.1790889
|
| 16 |
Chao-Sheng Cheng, Kai-Fan Jia, Ting Chen, Shun-Ya Chang, Ming-Shen Lin, Hsien-Sheng Yin, Ivo G. Boneca. Experimentally Validated Novel Inhibitors of Helicobacter pylori Phosphopantetheine Adenylyltransferase Discovered by Virtual High-Throughput Screening. PLoS ONE 2013; 8(9): e74271 doi: 10.1371/journal.pone.0074271
|
| 17 |
Kunqiang Cui, Weiqiang Lu, Lili Zhu, Xu Shen, Jin Huang. Caffeic acid phenethyl ester (CAPE), an active component of propolis, inhibits Helicobacter pylori peptide deformylase activity. Biochemical and Biophysical Research Communications 2013; 435(2): 289 doi: 10.1016/j.bbrc.2013.04.026
|
| 18 |
Qi Chen, Xiaohua Long, Yingjie Ji, Xiao Liang, Dongping Li, Hong Gao, Beili Xu, Ming Liu, Ying Chen, Yunwei Sun, Yan Zhao, Gang Xu, Yanyan Song, Lou Yu, Wei Zhang, Wenzhong Liu, David Y. Graham, Hong Lu. Randomised controlled trial: susceptibility‐guided therapy versus empiric bismuth quadruple therapy for first‐line Helicobacter pylori treatment. Alimentary Pharmacology & Therapeutics 2019; 49(11): 1385 doi: 10.1111/apt.15273
|
| 19 |
Louis Anthony Cox. Improving Risk Analysis. International Series in Operations Research & Management Science 2012; 185: 181 doi: 10.1007/978-1-4614-6058-9_6
|
| 20 |
Belagihalli M. Srikanta, Mysore A. Harish Nayaka, Shylaja M. Dharmesh. Inhibition of Helicobacter pylori growth and its cytotoxicity by 2-hydroxy 4-methoxy benzaldehyde of Decalepis hamiltonii (Wight & Arn); a new functional attribute. Biochimie 2011; 93(4): 678 doi: 10.1016/j.biochi.2010.12.009
|